This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug |
Toxicity |
Interaction Type |
Mechanism |
Reference |
|---|
| Disopyramide ((3737-09-5)) | Hypoglycaemia | Additive | Not fully established. The increased serum levels of disopyramide can
result in adverse effects such as QT prolongation and torsade de pointes,
and may result in enhanced insulin secretion and hypoglycaemia | Life-threatening interaction between clarithromycin and disopyramide
|
| Disopyramide ((3737-09-5)) | Torsade De Pointes | Additive | Not fully established. The increased serum levels of disopyramide can
result in adverse effects such as QT prolongation and torsade de pointes,
and may result in enhanced insulin secretion and hypoglycaemia | Life-threatening interaction between clarithromycin and disopyramide
|
| Rifampicin (13292-46-1) | Neutropenia | Additive | Rifampicin is enzyme inducers, which can increase the metabolism of other drugs by the liver, thereby reducing their serum levels. Rifampicin is recognised as being the more potent inducer | Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection
|
| Rifampicin (13292-46-1) | Uveitis | Additive | Rifampicin is enzyme inducers, which can increase the metabolism of other drugs by the liver, thereby reducing their serum levels. Rifampicin is recognised as being the more potent inducer | Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection
|
| Acenocoumarol (152-72-7) | Bleeding | Antagonistic | Not understood | Interaction between clarithromycin and oral anticoagulants
|
| Phenprocoumon (435-97-2) | Bleeding | Antagonistic | Not understood | Interaction between clarithromycin and oral anticoagulants
|
| Rifabutin (72559-06-9) | Neutropenia | Additive | Rifabutin is enzyme inducers, which can increase the metabolism of other drugs by the liver, thereby reducing their serum levels.Rifabutin is also a substrate for cytochrome P450 isoenzyme CYP3A4. It has been suggested that lower body weight and concurrent clarithromycin may result in toxic rifabutin serum levels | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers
|
| Rifabutin (72559-06-9) | Uveitis | Additive | Rifabutin is enzyme inducers, which can increase the metabolism of other drugs by the liver, thereby reducing their serum levels.Rifabutin is also a substrate for cytochrome P450 isoenzyme CYP3A4. It has been suggested that lower body weight and concurrent clarithromycin may result in toxic rifabutin serum levels | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers
|
| Disulfiram (97-77-8) | Epidermal Necrolysis | Additive | Not fully understood | Fulminant Hepatitis and Fatal Toxic Epidermal Necrolysis (Lyell Disease) Coincident With Clarithromycin Administration in an Alcoholic Patient Receiving Disulfiram Therapy
|
| Disulfiram (97-77-8) | Hepatitis Fulminant | Additive | Not fully understood | Fulminant Hepatitis and Fatal Toxic Epidermal Necrolysis (Lyell Disease) Coincident With Clarithromycin Administration in an Alcoholic Patient Receiving Disulfiram Therapy
|